

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>Woodard Jr Joseph Paul</u>  (Last) (First) (Middle) C/O BELLICUM PHARMACEUTICALS, INC. 2130 W. HOLCOMBE BLVD., STE. 800  (Street) HOUSTON TX 77030  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 04/25/2019	3. Issuer Name and Ticker or Trading Symbol <u>BELLICUM PHARMACEUTICALS, INC [ BLCM ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) SVP Clinical & Medical Affairs	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	2,415	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
Stock Option (right to buy)	(1)	11/12/2027	Common Stock 40,000	9.94	D	
Stock Option (right to buy)	(2)	01/31/2029	Common Stock 37,500	3.35	D	
Restricted Stock Units	(3)	(3)	Common Stock 15,000	(4)	D	

Explanation of Responses:

- 25% of the shares subject to the stock option vested on November 13, 2018, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
- 25% of the shares subject to the stock option vest and become exercisable on February 1, 2020, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.
- On November 13, 2017, the reporting person was granted restricted stock units (the "RSUs") for 15,000 shares. The RSUs vest in four annual installments beginning on November 13, 2018.
- Each RSU represents a contingent right to receive one share of the Issuer common stock.

Remarks:

EXHIBIT LIST: EX-24 POWER OF ATTORNEY

/s/ Joseph Paul Woodard, Jr

04/26/2019

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all, by these presents, that the undersigned hereby constitutes and appoints each of Richard A. Fair and Shane M. Ward, signing individually, the undersigned to:

- (1) execute for and on behalf of the undersigned, an officer, director or holder of 10% or more of a registered class of securities of Bellicum Pharmaceuticals
- (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute such Form 3, 4 or 5, complete and file such forms
- (3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interests of the undersigned.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary and proper to carry out the above and to execute the same.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with the SEC.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 15th day of April, 2019.

/s/ Joseph Paul Woodard, Jr  
(Signature)  
Joseph Paul Woodard, Jr  
(Print Name)

202180563 v1